{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+Seizures&page=2", "query": { "condition": "Refractory Seizures", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+Seizures&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-26T06:33:06.398Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01834482", "title": "Modified Atkins Diet Plus KetoCal for Adult Epilepsy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Epilepsy", "Seizure", "Medically Resistant Epilepsy", "Medically Resistant Seizures" ], "interventions": [ { "name": "Modified Atkins diet", "type": "DIETARY_SUPPLEMENT" }, { "name": "KetoCal", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 80, "start_date": "2013-03", "completion_date": "2017-09", "has_results": false, "last_update_posted_date": "2018-08-31", "last_synced_at": "2026-06-26T06:33:06.398Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01834482" }, { "nct_id": "NCT06952764", "title": "Epilepsy Cycles Longitudinal Monitoring to Inform Personalized Seizure-risk Estimation (ECLIPSE)", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Epilepsy (Treatment Refractory)" ], "interventions": [ { "name": "Seizure risk forecast", "type": "OTHER" }, { "name": "Control seizure risk forecast", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Insel Gruppe AG, University Hospital Bern", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2025-05-01", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2025-05-01", "last_synced_at": "2026-06-26T06:33:06.398Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06952764" }, { "nct_id": "NCT06309966", "title": "Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Focal Epilepsy" ], "interventions": [ { "name": "BHV-7000", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biohaven Therapeutics Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 390, "start_date": "2024-05-13", "completion_date": "2026-05", "has_results": false, "last_update_posted_date": "2026-04-17", "last_synced_at": "2026-06-26T06:33:06.398Z", "location_count": 65, "location_summary": "Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 55 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06309966" }, { "nct_id": "NCT00772603", "title": "Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Epilepsies, Partial" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "2400mg SPN-804", "type": "DRUG" }, { "name": "1200mg SPN-804", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Supernus Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 366, "start_date": "2008-11", "completion_date": "2010-11", "has_results": true, "last_update_posted_date": "2014-02-11", "last_synced_at": "2026-06-26T06:33:06.398Z", "location_count": 23, "location_summary": "Huntsville, Alabama • Northport, Alabama • Phoenix, Arizona + 20 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Northport", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00772603" }, { "nct_id": "NCT05469373", "title": "ESIS in Pediatric DRE", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Epilepsy" ], "interventions": [], "intervention_types": [], "sponsor": "Sarah Katie Ihnen", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "30 Years", "sex": "ALL", "summary": "1 Year to 30 Years" }, "enrollment_count": 86, "start_date": "2022-02-17", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2025-12-23", "last_synced_at": "2026-06-26T06:33:06.398Z", "location_count": 1, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05469373" }, { "nct_id": "NCT06081283", "title": "Antiseizure Medication in Seizure Networks at Early Acute Brain Injury", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Brain Injuries, Acute", "Brain Injuries, Traumatic", "Brain Ischemia", "Brain Hypoxia", "Hypoxia-Ischemia, Brain", "Heart Arrest", "Stroke", "Intracranial Hemorrhages", "Coma", "Persistent Vegetative State" ], "interventions": [ { "name": "Phenobarbital Sodium Injection", "type": "DRUG" }, { "name": "Levetiracetam", "type": "DRUG" }, { "name": "Lacosamide Injectable Product", "type": "DRUG" }, { "name": "Valproate Sodium", "type": "DRUG" }, { "name": "Fosphenytoin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of North Carolina, Chapel Hill", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Months", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Months to 70 Years" }, "enrollment_count": 5, "start_date": "2023-11-20", "completion_date": "2025-01-22", "has_results": true, "last_update_posted_date": "2025-11-14", "last_synced_at": "2026-06-26T06:33:06.398Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06081283" }, { "nct_id": "NCT01960075", "title": "Established Status Epilepticus Treatment Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Benzodiazepine Refractory Status Epilepticus" ], "interventions": [ { "name": "Fosphenytoin", "type": "DRUG" }, { "name": "Levetiracetam", "type": "DRUG" }, { "name": "Valproic acid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Virginia", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 478, "start_date": "2015-10", "completion_date": "2019-05", "has_results": true, "last_update_posted_date": "2021-06-14", "last_synced_at": "2026-06-26T06:33:06.398Z", "location_count": 65, "location_summary": "Tucson, Arizona • Los Angeles, California • Sacramento, California + 33 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01960075" }, { "nct_id": "NCT04378075", "title": "A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Mitochondrial Diseases", "Drug Resistant Epilepsy", "Leigh Disease", "Leigh Syndrome", "Mitochondrial Encephalopathy (MELAS)", "Pontocerebellar Hypoplasia Type 6 (PCH6)", "Alpers Disease", "Alpers Syndrome" ], "interventions": [ { "name": "Vatiquinone", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "PTC Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "20 Years", "sex": "ALL", "summary": "Up to 20 Years" }, "enrollment_count": 68, "start_date": "2020-09-28", "completion_date": "2023-12-27", "has_results": true, "last_update_posted_date": "2026-03-31", "last_synced_at": "2026-06-26T06:33:06.398Z", "location_count": 12, "location_summary": "San Diego, California • Stanford, California • New Haven, Connecticut + 7 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04378075" }, { "nct_id": "NCT01713946", "title": "A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Tuberous Sclerosis Complex-associated Refractory Seizures" ], "interventions": [ { "name": "RAD001", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Antiepileptic drug (1 to 3 only)", "type": "DRUG" }, { "name": "open label RAD001 (only used for post-extension phase)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "2 Years to 65 Years" }, "enrollment_count": 366, "start_date": "2013-04-29", "completion_date": "2017-10-25", "has_results": true, "last_update_posted_date": "2018-11-07", "last_synced_at": "2026-06-26T06:33:06.398Z", "location_count": 22, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 18 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01713946" }, { "nct_id": "NCT00448539", "title": "Open-Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Refractory Partial Onset Seizures" ], "interventions": [ { "name": "Rufinamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "12 Years to 80 Years" }, "enrollment_count": 286, "start_date": "2007-03-15", "completion_date": "2010-05-14", "has_results": true, "last_update_posted_date": "2019-11-22", "last_synced_at": "2026-06-26T06:33:06.398Z", "location_count": 27, "location_summary": "Mobile, Alabama • Little Rock, Arkansas • Bradenton, Florida + 22 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Bradenton", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Loxahatchee Groves", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00448539" } ] }